Extedo adds two to management board
Directors will be based in Germany and US respectively
Schmid joins the organisation as president and now shares day-to-day operational responsibilities with chief executive Tore Bergsteiner.
Dude has taken the position of managing director at Extedo Inc in the US, to support the organisation’s expansion in North America.
Schmid will head up the global marketing and sales organisation as well as the Product Management Unit, which are key areas for Extedo. He will be based in Ottobrunn, Germany.
Schmid has more than 15 years of experience in management consulting, marketing and sales.
Dude will be based in West Chester, PA. He has more than 20 years of experience in the IT services and software industries with Prime Technology Group, Glemser Technologies, First Consulting Group and Thomson Financial.
You may also like
Regulatory
WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Regulatory
FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus
AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Britain's biotech potential (part I): world-class science, second-class support?
The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
Manufacturing
FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing
A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain